Observational studyPloS one2020

Incidence of major and clinically relevant non-major bleeding in patients prescribed rivaroxaban for stroke prevention in non-valvular atrial fibrillation in secondary care: Results from the Rivaroxaban Observational Safety Evaluation (ROSE) study.

Alison Evans et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.